ASCO 2026 - Peter Collins is the Chief Executive Officer (CEO) of CelLBxHealth plc29 May 2026 15:39
Peter Collins is the Chief Executive Officer (CEO) of CelLBxHealth plc, a circulating tumour cell (CTC) insights company specializing in advanced liquid biopsy and cell-harvesting platforms.At the ASCO 2026 Annual Meeting, Collins and his team attended to showcase and discuss the company's progress and capabilities. His participation and commentary focused on several core initiatives:
Commercial Acceleration: Following a £6.6 million restructuring and cost-cutting overhaul, Collins noted that CelLBxHealth is targeting rapid commercial expansion just as industry demand for circulating tumour cell (CTC) analysis accelerates.Role in Liquid Biopsies: At ASCO and other oncology conferences, Collins has heavily advocated for the value of CTCs, emphasizing that they offer unique expression and proteomics data that traditional tissue samples or ctDNA alone cannot provide.Key Collaborations: He has been actively building partnerships to integrate CTC analysis into standard cancer care, collaborating with institutions like The Royal Marsden and major global pharmaceutical Including Astrazeneca companies.
CelLBxHealth plc (AIM: CLBX), led by newly appointed CEO Peter Collins, has dramatically transformed its financial health ahead of the ASCO 2026 Annual Meeting. Late last year, the oncology diagnostics company faced a critical cash runway extending only into early 2026. However, a successful £6.8 million fundraise combined with a massive £6.6 million cost-cutting restructuring has officially extended CelLBxHealth's cash runway to the third quarter of 2027.Peter Collins is leveraging this newfound financial stability at the American Society of Clinical Oncology (ASCO) 2026 conference in Chicago to aggressively push the company's circulating tumor cell (CTC) platform into standard liquid biopsy workflows.
Sign In
Follow the stocks
